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compliance for these days exceeded 90%. Evidence for
back and forward filling of paper diary cards was ob-
served. For the compliance-enhanced electronic diary, the
actual compliance rate was 93%.
CONCLUSIONS: Data from paper-based diaries are of
questionable validity, given that many of their entries are
not completed as required by the protocol. Science-based
electronic diaries can produce high rates of patient com-
pliance in the field. Improved methods for data collection
should encourage researchers in the pharmaceutical in-
dustry to aggressively evaluate electronic PRO (ePRO)
data to help differentiate their products.
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OBJECTIVE: Increasingly, federal authorities are request-
ing power calculations for secondary endpoints in clinical
trials, including patient reported outcomes (PRO). How-
ever, most PRO measures do not provide power calcula-
tions in their manuals; if provided, they are often based on
mixed samples of males and females. It is well docu-
mented that female and male PRO scores often differ.
Thus when designing women’s health trials, it may be
worthwhile to conduct power calculations using women’s
PRO scores and standard deviations. This study presents
the power and sample-size calculations for a variety of
questionnaires used in women’s health studies.
METHODS: The Menopause Quality of Life question-
naire (MENQOL), Women’s Health Questionnaire (WHQ),
Psychological General Well-Being Index (PGWB), and
Short Form 36 and 12 (SF-36/SF-12) were assessed. Pub-
lished information on scores and standard deviations in
female populations were used to determine sample sizes
needed to detect differences between two experimental
groups, post-intervention.
RESULTS: Results varied by questionnaire, due in part to
varying score ranges across questionnaires. For example, to
achieve 90% power with a ten-point difference the follow-
ing sample sizes per treatment arm were required: 158
women when using the MENQOL vasomotor score (range:
0–100); 47 women when using the WHQ total score (range:
0–102); 70 women when using the PGWB total score
(range: 22–132); 24 and 21 women when using the SF-36
and SF-12 Physical Component Summary (no floor/ceiling).
CONCLUSION: When calculating sample sizes, it is nec-
essary to keep in mind the questionnaire’s possible score
range in order to ensure that the power calculation is
based on a clinically meaningful difference between treat-
ment groups. These results may be used to help calculate
sample sizes needed to achieve sufficient power to detect
statistically significant differences in women’s health tri-
als for these widely used measures.
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OBJECTIVES: The availability of reliable methods for im-
puting hospital costs (e.g., relative values from the U.S. diag-
nosis-related group (DRG) payment system, cost weights
and average length of stay (LOS) estimates from the Austra-
lian refined DRG system, or average LOS from the French
Patient Homogeneous Groups), allows one to address two
design questions related to the collection of hospital unit
cost data for use in multinational clinical trials with eco-
nomic endpoints: 1) In individual countries, for how many
types of hospitalization should estimates be obtained? 2)
For how many countries should they be obtained?
METHODS: We addressed these questions by assuming
that unit cost estimates for 47 types of hospitalization
collected in four western European countries represented
the universe of hospitalizations. This assumption pro-
vided a population estimate against which we could mea-
sure the error associated with imputations in samples
drawn from the population. To answer the first question,
we: 1) randomly sampled subsets of hospitalization types
from this population and used them to develop imputa-
tion regressions; 2) used the results of the regressions to
impute costs from the remaining hospitalization types,
and 3) estimated measures of imputation error within
each sample. To answer the second question, we per-
formed a similar analysis, but instead sampled countries.
RESULTS: We found that the imputation error decreased
as the number of types of hospitalization and countries
sampled increased, but that the rate of reduction in error
shrank. We also found that error was minimized by ob-
taining estimates for fewer types of hospitalization from
more countries than the reverse.
CONCLUSION: The availability of reliable methods for
imputing hospitalization costs allows one to economize
on data collection. Our experiment suggested that col-
lecting a small number of estimates (in our data, approxi-
mately 25) in as many countries as is feasible minimizes
imputation error.
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